Enrollment will begin in January 2026 Participants will be treated with buntanetap for 36 months The study aims to enroll 500 patients MALVERN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug...Read more
Toronto, Ontario--(Newsfile Corp. - December 18, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in diagnostic and prognostic innovation through advanced telomere analytics, today announced the initiation of a new multiple myeloma (MM)...Read more
Enrollment momentum accelerates as Company advances toward full enrollment White Bear Lake, Minnesota--(Newsfile Corp. - December 18, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing...Read more
-- Innovative single-device solution integrates proven FemVue and FemChec® technologies to support fallopian tube evaluation and improve workflow efficiency-- ATLANTA, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and...Read more
First and only delivery system designed specifically for premature infants with a patent ductus arteriosus (PDA), a life-threatening opening in their heart New delivery system enables precise placement of Abbott's Amplatzer Piccolo Occluder in the tiniest babies A PDA requiring treatment is...Read more
MINNEAPOLIS / Dec 18, 2025 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS), today announced completion of a productive in-person...Read more
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Eli Lilly | 18.21 1.75 | $1,060.00 |
| Nutex Health | 7.84 4.93 | $166.84 |
| Penumbra | 6.09 1.97 | $315.35 |
| Intuitive | 5.03 0.90 | $561.89 |
| Mettler-Toledo | 4.74 0.34 | $1,389.42 |
| Bolt Biotherapeutics | 4.60 821.43 | $5.16 |
| Movano Health | 4.45 143.09 | $7.56 |
| Integer | 4.39 5.92 | $78.52 |
| McKesson | 4.04 0.50 | $810.56 |
| Forte Biosciences | 3.99 16.12 | $28.74 |
| Alnylam Pharmaceuticals | 3.94 1.00 | $396.04 |
| Ligand Pharmaceuticals | 3.82 1.96 | $198.41 |
| Praxis Precision Medicines | 3.40 1.28 | $269.26 |
| Insulet | 3.31 1.14 | $292.88 |
| Medpace | 3.14 0.56 | $560.21 |
| Disc Medicine | 2.89 3.30 | $90.44 |
| Abivax | 2.79 2.52 | $113.61 |
| Veeva Systems | 2.64 1.23 | $218.10 |
| Company | Volume | Last Trade |
|---|---|---|
| Akari Therapeutics | 384,809,443 | $0.25 |
| WORK Medical Technology | 254,608,248 | $0.06 |
| Athira Pharma | 81,019,670 | $6.70 |
| VYNE Therapeutics | 68,843,292 | $0.59 |
| Tenaya Therapeutics | 48,569,556 | $0.67 |
| Pfizer | 45,523,151 | $25.04 |
| Recursion | 34,744,442 | $4.46 |
| Vistagen | 32,332,079 | $0.75 |
| Insmed | 27,734,707 | $166.55 |
| Incannex Healthcare | 25,802,664 | $0.42 |
| Humacyte | 25,298,187 | $1.11 |
| ImmunityBio | 25,120,385 | $2.09 |
| Moderna | 19,742,267 | $30.95 |
| Pyxis Oncology | 19,675,547 | $1.69 |
| PacBio | 18,810,807 | $1.93 |
| Viatris | 17,505,245 | $11.94 |
| Femasys | 16,999,389 | $0.79 |
| Applied Therapeutics | 16,747,687 | $0.12 |
| Outlook Therapeutics | 16,232,738 | $2.07 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. The company's lead cell therapy asset is NXC-201 in multiple myeloma...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
